Skip to content

The Clinical Value of High-Flow Nasal Oxygen in Pediatric Rapid Sequence Induction: An Analysis Based on Its Effect of Prolonging Non-Hypoxemic Apneic Time

The Clinical Value of High-Flow Nasal Oxygen in Pediatric Rapid Sequence Induction: An Analysis Based on Its Effect of Prolonging Non-Hypoxemic Apneic Time

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126442
Enrollment
Unknown
Registered
2026-06-09
Start date
2026-06-22
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxemia during anesthesia induction, perioperative atelectasis

Interventions

experimental group:After pre-oxygenation with HFNC, chin support is provided, and while assisted ventilation is discontinued, high?flow oxygen is continued via HFNC at flow rates set according to unif
control group:After pre-oxygenation, only chin support is provided (to maintain airway patency), the mask is removed, and oxygen supply is stopped.

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Aged 3–6 years, with preoperative SpO2 >=98%; 2. Scheduled for surgery under general anesthesia with endotracheal intubation or laryngeal mask airway; 3. ASA physical status I or II; 4. Children who have completed unified fasting for 8 hours and abstained from liquids for 2 hours preoperatively, meeting the standard preoperative fasting guidelines for anesthesia; 5. Written informed consent has been signed by the parent or legal guardian, agreeing to the child’s participation in this study.

Exclusion criteria

Exclusion criteria: 1. Presence of circulatory system disease with hemodynamic instability; 2. Congenital airway malformation, history of difficult airway, or complete upper airway obstruction; 3. Presence of nasal bone or skull base fracture; 4. Received any treatment or intervention that may affect airway management prior to the trial; 5. Known allergy to the equipment or materials used in the trial; 6. Recent (<2 weeks) confirmed or suspected upper respiratory tract infection; 7. Abnormal nasal structure preventing effective placement of high-flow nasal cannula (HFNC).

Design outcomes

Primary

MeasureTime frame
non-hypoxic apnea time;

Secondary

MeasureTime frame
lung ultrasound score;SpO2 desaturation rate;SpO2 nadir;Pediatric Anesthesia Emergence Delirium (PAED) scale;

Countries

China

Contacts

Public ContactHu Wei

Shenzhen Children's Hospital

1059581483@qq.com+86 187 2806 1883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026